Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Combination therapy for dyslipidemia.

Craig W Spellman1

  • 1Department of Internal Medicine, University of North Texas Health Science Center at Fort Worth, USA. Cspel74111@aol.com

The Journal of the American Osteopathic Association
|February 8, 2003
PubMed
Summary

Achieving low-density lipoprotein cholesterol (LDL-C) targets is crucial for reducing coronary heart disease (CHD) risk. Combination therapy, including novel agents like ezetimibe, improves lipid management and patient outcomes.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Effect of inpatient electroencephalography on clinical decision making.

The Journal of the American Osteopathic Association·2013
Same author

Effect of vitamin D replacement on insulin sensitivity in subjects with vitamin D deficiency.

Journal of investigative medicine : the official publication of the American Federation for Clinical Research·2012
Same author

Common patient concerns about the use of glucagon-like peptide-1 receptor agonists in diabetes mellitus management.

The Journal of the American Osteopathic Association·2012
Same author

Incorporating glucagon-like peptide-1 receptor agonists into clinical practice.

The Journal of the American Osteopathic Association·2012
Same author

Diabetes--it's the basics that count.

The Journal of the American Osteopathic Association·2011
Same author

Pharmacology of GLP-1 agonists: describing the therapeutic potential to patients.

The Journal of the American Osteopathic Association·2011

Area of Science:

  • Cardiology
  • Pharmacology
  • Metabolic Disorders

Background:

  • National Cholesterol Education Program (NCEP) Adult Treatment Panel III (ATP III) guidelines emphasize low-density lipoprotein cholesterol (LDL-C) targets for coronary heart disease (CHD) risk reduction.
  • Despite lifestyle changes, many patients with dyslipidemia fail to reach lipid targets, necessitating pharmacotherapy.
  • Current achievement rates for LDL-C goals remain low, even in patients with existing CHD.

Purpose of the Study:

  • To review the pharmacotherapeutic effects of combination lipid-lowering therapy.
  • To summarize the strengths and weaknesses of current lipid-lowering drug combinations.
  • To identify the impact of ezetimibe, a novel cholesterol absorption inhibitor, on the LDL-C treatment algorithm.

Main Methods:

  • Review of pharmacotherapeutic effects of combination therapy.
  • Summary of current lipid-lowering drug combinations, including strengths and weaknesses.
  • Analysis of ezetimibe's role in cholesterol management.

Main Results:

  • Combination therapy significantly enhances the likelihood of achieving target lipid levels.
  • Therapeutic modalities targeting both endogenous and exogenous cholesterol pathways are ideal.
  • Ezetimibe presents a potential new option within the LDL-C treatment algorithm.

Conclusions:

  • Early and aggressive use of effective lipid-lowering agents is critical for reaching treatment goals.
  • Combination drug therapy is essential for improving lipid management in a majority of patients.
  • Ezetimibe offers a promising addition to the therapeutic arsenal for managing dyslipidemia and reducing CHD risk.

Related Experiment Videos